Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (488)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03462719 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(GLOW) | active not recruiting | Phase 3 | 211 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 28, 2026 | clinicaltrials |
| NCT03560752 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | active not recruiting | Phase 1 | 34 | City of Hope Medical Center |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT05424822 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 1 | 167 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05507827 | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | active not recruiting | Phase 1 | 22 | Melody SmithOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 652 | BeOne MedicinesINDUSTRY | 21 | Sep 28, 2026 | clinicaltrials |
| NCT06524375 | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period(BRAVE) | active not recruiting | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting | Phase 3 | 282 | Loxo Oncology, Inc.INDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06476665 | A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. | active not recruiting | — | 12 | PfizerINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05044039 | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | active not recruiting | Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04732845 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | active not recruiting | Phase 1 | 18 | Benjamin TomlinsonOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06170671 | REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania(REACH) | active not recruiting | — | 250 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | active not recruiting | — | 1,836 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02537613 | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 488 | National Cancer Institute (NCI)NIH | 4 | Sep 21, 2026 | clinicaltrials |
| NCT05879133 | HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia | active not recruiting | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02194387 | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | active not recruiting | N/A | 337 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05944562 | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01841723 | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06002828 | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | active not recruiting | — | 2,000 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 155 | AstraZenecaINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01) | active not recruiting | Early Phase 1 | 18 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | active not recruiting | N/A | 80 | University of West AtticaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01044069 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment(INVISE) | active not recruiting | Phase 1 | 10 | Kite, A Gilead CompanyINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT02131584 | Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03824483 | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | active not recruiting | Phase 2 | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04635384 | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test(ACROBAT) | active not recruiting | — | 307 | CareDxINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05140369 | CLL Therapy Approaches in Russia(CLL registry) | active not recruiting | — | 6,000 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05470777 | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | active not recruiting | Phase 2 | 37 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05707273 | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04262843 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | active not recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04315324 | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | active not recruiting | Phase 1 / Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 547 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 3 | 529 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 465 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05763290 | Childhood Cancer Survivors' Affective Response to Exercise | active not recruiting | — | 125 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials